日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Research and development innovations poised to cure more ills

By David Ho in Hong Kong | China Daily | Updated: 2019-04-10 09:28
Share
Share - WeChat

In mid-December, Shanghai Junshi Biosciences raised $394 million after pricing a Hong Kong initial public offering at the bottom of a marketed range.

At the same time, the Shanghai company's new drug Toripalimab was conditionally approved for the treatment of melanoma, becoming the first made-in-China immuno-therapy treatment for cancer to be approved by the National Medical Products Administration.

For Lewis Ho, a partner in the life sciences practice at law firm Loeb & Loeb, the start of the nation's healthcare research and development can be traced to 2006.

At the time, Ho was working with GlaxoSmithKline in Shanghai, and in 2007, GSK was one of the first multinationals to open a research and development center in China, focusing on neurodegenerative diseases.

By 2012, a report by management consultants McKinsey & Company said that 13 of the top 20 global drugmakers had set up R&D centers in China since 2006.

Ho said: "This sparked a new wave of research in the country. Government, academic and commercial organizations needed researchers. Chinese scientists were coming back from abroad and discovering a whole new world. Many of them went on to set up their own companies."

Funding remained a problem, particularly since the Hong Kong Stock Exchange, a big source of capital-raising for many companies in Asia, did not allow listings from companies that had not yet made a profit. But that rule changed last year.

"Many of these companies are maturing. It's a great time for the Hong Kong Stock Exchange to catch the next wave," Ho said.

Hong Kong Exchanges and Clearing posted new rules in April last year, which included allowing listings by biotech companies that had yet to make any money.

As of Dec 24, five such companies had listed on the Hong Kong bourse under the new rules. Another eight are in line for listing consideration.

HKEX has also formed a Biotech Advisory Panel - comprising industry experts - to advise and assist in the review of listing applications from biotech companies applying under the new regimen.

Ho said the first batch of companies that "dipped their toes in the HKEX pond" are safe bets. All of them have products in phase 3 clinical trials.

He expects that as the market matures and investors become more familiar with the biotech scene, more companies with early-stage products will start listing.

Ho said biotech companies on the Chinese mainland are choosing to list in Hong Kong because of the market size and the speed at which listings are approved.

"With the Shanghai Stock Exchange, it is harder to estimate when a listing will be approved, due to regulatory uncertainty, longer processing time and priority treatment for different industries. In Hong Kong, you get a sense of the IPO in about six months to a year," he said.

"More mature markets, like the Nasdaq Stock Exchange (in the United States) are too big for these emerging companies," he added.

"The Chinese government wants to push its biotech industries to succeed. Twelve years ago, there were no Chinese companies in the top 100 - now, there are about three on that list, with interesting products to launch," Ho said.

The country has also been revamping its regulatory system. In September, the China Food and Drug Administration was restructured and renamed the National Medical Products Administration.

The NMPA has introduced faster approvals for new drugs and added a priority list of 48 drugs for rare diseases. Those chosen were approved by the authorities in the United States, the European Union and Japan, but have not been registered in China for the past decade.

"The registration and approval process is happening a lot faster than before. Some companies are finding that they have been given approval two years before they expect it. So now there is a mad scramble to recruit sales representatives and for sales preparation," Ho said.

The inclusion of drugs in reimbursement programs is an area that needs to be improved.

The national reimbursement drug list determines the framework for the drugs covered by insurance at national level. It consists of two categories: List A drugs that are clinically necessary and sufficiently affordable to be fully reimbursed, and List B drugs that are newer, more expensive and require patients to pay 10 to 30 percent of the price.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 成人亚洲综合 | 国产精品美女久久久免费 | 国产孰妇精品AV片国产m3u8 | 亚洲二区视频 | 亚洲高清免费观看 | 精品在线播放 | 欧美日韩综合视频 | 一区二区三区在线 | 夜夜摸夜夜爽 | 国产日韩欧美不卡 | 九九综合九九 | 成人综合在线观看 | 婷婷综合缴情亚洲五月伊 | 国产精品男人的天堂 | 中文字幕在亚洲第一在线 | 日韩精品视频免费在线观看 | 日韩大尺度电影在线观看 | 日本a在线 | 色婷婷成人做爰A片免费看网站 | 国产精品国产三级国产aⅴ入口 | 香蕉福利久久福利久久香蕉 | 一级毛片视频免费观看 | 新97人人模人人爽人人喊 | 欧美成人h版在线观看 | 国产第一页浮力 | 亚洲一区二区免费视频 | 成年人免费网 | 999精品嫩草久久久久久99 | 日韩手机在线 | 免费观看欧美一级片 | 视频一区二区久久 | 日韩在线观看中文字幕 | 91看片在线免费观看 | 日本高清在线精品一区二区三区 | 久久国产精品一区二区 | 狠狠撸电影院 | 99精品一区二区 | 国产乱码精品1区2区3区 | 成人av网站在线观看 | 久久99精品国产99久久 | 国产精品免费一区二区三区都可以 |